Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Harding, James J; Lowery, Maeve A; Shih, Alan H; Schvartzman, Juan M; Hou, Shengqi; Famulare, Christopher; Patel, Minal; Roshal, Mikhail; Do, Richard K; Zehir, Ahmet; You, Daoqi; Selcuklu, S Duygu; Viale, Agnes; Tallman, Martin S; Hyman, David M; Reznik, Ed; Finley, Lydia W S; Papaemmanuil, Elli; Tosolini, Alessandra; Frattini, Mark G; MacBeth, Kyle J; Liu, Guowen; Fan, Bin; Choe, Sung; Wu, Bin; Janjigian, Yelena Y; Mellinghoff, Ingo K; Diaz, Luis A; Levine, Ross L; Abou-Alfa, Ghassan K; Stein, Eytan M; Intlekofer, Andrew M.
; 8(12): 1540-1547, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30355724
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.